IFW

PTO/SB/21 (09-04) MODIFIED

			Application Number:	10/696,255			
PETRANSMITTAL			Filing Date:		October 29, 2003 Kimberly Kline		
			First Named Inventor:				
FORM			Art Unit:	1636			
"" 01.100 E.			Examiner Name:	Unknown			
Total Number of Barges in this Submission:			Attorney Docket Number:				
T I I Bello	Ses in ans odomission				R:228US		
			ENCLOSURES (check all that	арріу			
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Form PTO-1449 References C1-C4 Certified Copy of Priority Documents Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 Declaration(s) Copy of Notice of Missing Parts R		Lid Pet Ag Por CI Ad Tet	Drawings(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Statement under 37 CFR §3.73(b) Designation of Patent Practitioners Terminal Disclaimer Request for Refund CD, Number CD(s) Landscape Table on CD		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below) Check in the amount of \$ Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: 50-1212/CLFR:228US Sequence Statement Paper Copy of Sequence Listing Computer Readable Form (CRF) Postcard		
		Remar	rks:				
		CALCINI A COLUM	DE OE ABBUTOARM A TOTAL	*****	OR ACTIVE		
SIGNATURE OF APPLICAN							
Firm Name Fulbright & worski, L.I. Signature		orski, L.I.P.			Customer Number 32425		
Printed Name David L. Parker					Reg. No.	32,165	
Date April 29, 2005							
		CIETO	IEIOAME OF ME LYGS STEEL				
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being factorial transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Market Denty, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:							
Signature		(A			-		
Typed or Printed Name		David L. Par	ker		Date A	pril 29, 2005	



In re Application of: Kimberly Kline *et al*.

Serial No.: 10/696,255

Filed: October 29, 2003

For: MUTANT p53 PROTEINS AND USES

THEREOF

Group Art Unit: 1636

Examiner: Unknown

Atty. Dkt. No.: CLFR:228US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P.O. By 1450, Alexandria, VA 22313-1450, on the date below:

April 29, 2005

Date

David L. Parker

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/CLFR:227US.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Attorney for Applicants

David L. Parker

Reg. No. 32,165

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

April 29, 2005

25527808.1

ı		6	PEVO					Page 1 of	
Form PTO-1449 (modified) NAY 022005				Atty. Docket No. CLFR:228US			Serial No. 10/696,255		
		N DISCLOSURE S		Kimberly Kli	ne <i>et al</i> .				
		2 10 0 2 0 3 0 11 2		Filing Date:		Gr	oup:		
(Use several sheets if necessary)				October 29, 2003 1636					
U.	U.S. Patent Documents Foreign P.				Patent Documents Other Art				
					ee Page 1 See Page 1				
					<u> </u>	-			
			U.S. Pate	ent Docum	ents				
Exam. Init.	Ref. Des.	Document Number	Date	Name		Class	Sub Class	Filing Date of App.	
		F	oreign Pa	itent Docui	ments				
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class		anslation Yes/No	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation			
	C1	Bennett, "Mechanisms of p53-induced apoptosis," <i>Biochem. Pharmacol.</i> , 58(7):1089-1095, 1999.			
	C2	O'Connor et al., "Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents," Cancer Res., 57:4285-4300, 1997.			
	C3	Smith et al., "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype," Oncogene, 18:6063-6070, 1999.			
	C4	Yang et al, "Induction of retinoid resistance in breast cancer cells by overexpression of cJun," <i>Cancer Res.</i> 57:4652-4661, 1997.			

25527809.1

tP

E v				m	_	
$\mathbf{E}\mathbf{x}$	А	VI	IN	Ю,	к	Ξ

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.